Research and Markets: Immune/Inflammatory Disease: Early-Stage R&D Technologies and Dealmaking - Now Available
* Reuters is not responsible for the content in this press release.
DUBLIN--(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/ac3040/immuneinflammator) has announced the addition of Decision Resources, Inc.'s new report "Immune/Inflammatory Disease: Early-Stage R&D Technologies and Dealmaking" to their offering. Today's leading autoimmune/inflammatory disease drugs are blockbusters, but what are the remaining unmet needs and next opportunities? Dealmaking patterns indicate that Big Pharma continues to look to small technology companies to tap opportunities to treat underserved diseases and offer improved administration options. While the value of the novel agents in development remains unproved, early stage platforms and pipelines house the next innovations in these disease states. Get the Answers You Need to Shape Your Strategy * Although efficacious, current therapies for inflammatory and autoimmune diseases do not successfully treat all patients. What novel mechanisms of action are in development? What technologies offer treatment potential? * Much of the innovation in drug discovery and design occurs in small companies. What companies are developing novel approaches to treat infl ammatory diseases? What collaborations have they forged with Big Pharma? * Although the inflammatory cascade is central to most of the autoimmune diseases, the specific etiology of many diseases remains unknown. What are companies doing to further the understanding of these diseases? Scope * Current market: 2008 sales, market-leading products, leading companies. * Novel targets for drug development: MAP kinases, Janus kinases, toll-like receptors, novel interleukins, NF-?B, PDE4. * Novel technologies for drug development: RNA therapeutics, stem-cell therapy. * Development and dealmaking data: 8 tables that identify developmental compounds and industry and academic alliances. * Company profiles: Archemix, Array BioPharma, Cellzome, Dynavax, Regulus Therapeutics. Key Topics Covered: * Executive Summary * Strategic Considerations * Stakeholder Implications * Introduction * What Market Awaits Innovative Therapies? * Novel Approaches to Infl ammation/Autoimmune Disease Treatment * Novel Targets * MAP Kinases * Jak * Toll-Like Receptors * Novel Interleukins * Nuclear Factor-Kappa B * Phosphodiesterase 4 * Novel Technologies * RNA-Based Therapeutics * Stem-Cell Therapy * Company Profi les * Archemix * Array BioPharma * Cellzome * Dynavax * Regulus Therapeutics * Outlook Some Companies Mentioned in the Report: * Abbott * Adeona Pharmaceuticals * Amgen * Anacor Pharmaceuticals * Anesiva * AnGes MG * Archemix * Ardea * Array BioPharma * AstraZeneca * Boehringer Ingelheim * Bristol-Myers Squibb * Celgene * Cellzome * Centocor * Cytokine Pharmasciences * Cytos Biotechnology * Dainippon Sumitomo * Dynavax * Eisai * Eli Lilly * Genzyme * GlaxoSmithKline * Glenmark Pharmaceuticals * Hutchison Medipharma * Idera Pharmaceuticals * Incyte * Institute of Medicinal Molecular Design For more information visit http://www.researchandmarkets.com/research/ac3040/immuneinflammator Research and Markets Laura Wood Senior Manager press@researchandmarkets.com Fax from USA: 646-607-1907 Fax from rest of the world: +353-1-481-1716 Copyright Business Wire 2009
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters